Consequently, restoring ACh levels has become a primary therapeutic strategy in AD therapeutics.[11] It is well established that two cholinesterase (ChE) enzymes, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), are responsible for the hydrolysis of ACh within the human brain. The gene discussed is ACHE; the disease is Alzheimer disease.